The University of Arizona




UA Life Science Research - BioGate


Raymond B Nagle MD, PhD

Professor and Associate Head


Raymond Nagle Contact Information

Address: Arizona Cancer Center
PO 245024
Tucson, AZ 84724-5-24
Phone: 520-626-6032
E-Mail: rnagle@email.arizona.edu

Degrees
Department Affiliations
Program Affiliations

home Faculty Homepage

Research Interests

My research interests focus on factors involved in prostate cancer progression. I am particularly interested in changes in the extracellular matrix and am currently studying the differential effect of Laminin 5 and Laminin 10 on cell signaling. In addition, I am interested in the development of biomarkers, particularly differentiating aggressive from non-aggressive cancers.

The work in my laboratory primarily focuses on the interaction of cell surface molecules with the extracellular matrix, and migration of cells.  These problems are basic to our understanding of the invasion and spread of cancer.  We have focused on prostate cancer and use a variety of approaches including protein chemistry, immunohistochemical analysis, ultrastructural analysis, and molecular procedures.  Our work includes model systems using prostate cell lines, immunodeficient mice, and human tissues.  Opportunities to learn technical procedures include monoclonal antibody production, transfection (using cDNA), and analysis of messenger RNA at the cellular level using in-situ hybridization.

Selected Publications

Gordon MS< Hussey M, Nagle RB, Lara PN et al. Dec 2009. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol, 27:5788-93

Ports MO, Nagle RB, Pond GD, Cress AE. Jun 2009. Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen adtivator-mediated cleavage and delayed human prostate bone metastasis. Cancer Res, 69:5007-14

Riley CJ, Engelhardt KP, Saldanha JW, Qi W, Cooke LS, Zhu Y, Narayan ST, Shakalya K, Croce KD, Georgiev IG, Nagle RB. Mar 2009. Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer. Cancer Res, 69:1933-40

King TE, Pawar SC, Majuta L, Sroka IC, Wynn D, Demetrious MC, Nagle RB, Porreca F, Cress AE. Oct 2008. The role of alpha 6 integrin in prostate cancer migration and bone pain in a novel xenograft model. PLoS One, 3:e3535


Update your profile